OBJECTIVES: Data on real-world outcomes and healthcare resource utilisation (HRU) in multiple myeloma (MM) in Europe is limited. This study aimed to provide insights into real-world outcomes (i.e. PFS and OS) and HRU of MM patients in The Netherlands using data from the PHAROS-registry. METHODS: MM patients starting first-, second- or third-line therapy ≥2008 were selected from the PHAROS-registry. Note that not all patients in the analysis on second- and third-line were included in the analysis on previous lines (e.g. a patient could have started second-line therapy ≥2008, while having started first-line therapy <2008). The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS) and HRU. RESULTS: First-line thalidomide-based regimens were prescribed to 66% of patients (n=608) and bortezomib-based regimens to 15% (n=139). 19% (n=170) received another first-line regimen. Median OS (95% confidence interval [CI]) in first- (n=917), second- (n=583) and third-line (n=283) were 37.5(34.8–41.8), 19.7(17.2–22.9) and 13.9(10.5–16.6) months, respectively. Median PFS (95% CI) were 18.0(16.3–18.9), 8.9(7.9–9.7) and 6.4(5.5–7.2) months, respectively. Large differences were seen between subgroups in all treatment-lines, e.g. median OS from first-line therapy ranged from 31.9(29.1-35.4) to 64.6(53.2-not reached) months for patients >65 and patients ≤65, respectively, and was 32.2(29.2-35.5) for patients without prior stem cell transplantation (SCT) (median OS not reached for patients with prior SCT). Similarly, median PFS from first-line therapy ranged from 16.2(14.5-17.9) to 22.6(19.8-26.5) months for patients >65 and patients ≤65, respectively, and from 15.2(13.6-17.0) to 32.0(26.2-36.5) for patients without or with prior SCT, respectively. Mean (standard deviation [SD]) number of inpatient days per month were 1.7(3.4), 1.4(3.2) and 2.3(4.6) in first, second and third-line, respectively. CONCLUSIONS: In patients receiving first-line therapy for MM between 2008 and 2012 in The Netherlands, median OS was approximately three years. Large differences were observed between subgroups.